滨州市美人间美甲加盟电话多少钱(永川区指匠美甲加盟电话多少钱) (今日更新中)

The demand for mail-in ballots is surging. Election workers need training. And polling booths might have to be outfitted with protective shields during the COVID-19 pandemic.As officials prepare for the Nov. 3 election, one certainty is clear: It’s coming with a big price tag.“Election officials don’t have nearly the resources to make the preparations and changes they need to make to run an election in a pandemic,” said Wendy Weiser, head of the democracy program at the Brennan Center for Justice. “We are seeing this all over the place.”The pandemic has sent state and local officials scrambling to prepare for an election like few others, an extraordinary endeavor during a presidential contest, as virus cases continue to rise across much of the U.S.COVID-related worries are bringing demands for steps to make sure elections that are just four months away are safe. But long-promised federal aid to help cash-starved states cope is stalled on Capitol Hill.The money would help pay for transforming the age-old voting process into a pandemic-ready system. Central to that is the costs for printing mail-in ballots and postage. There are also costs to ensure in-person voting is safe with personal protective equipment, or PPE, for poll workers, who tend to be older and more at risk of getting sick from the virus, and training for new workers. Pricey machines are needed to quickly count the vote.Complicating matters is President Donald Trump’s aversion to mail-in balloting. With worrisome regularity, he derides the process as rigged, even though there’s no evidence of fraud and his own reelection team is adapting to the new reality of widespread mail-in voting.“As cases of coronavirus in this country rise, it’s vital that all voters be able to cast their ballots from home, to cast their ballots by mail,” said Sen. Amy Klobuchar, D-Minn.A huge COVID response bill passed by the House in May contains a whopping .6 billion to help states with their elections, but the Senate won’t turn to the measure until late July. Republicans fought a 0 million installment of election aid this March before agreeing to it.But key Senate Republicans seem likely to support more election funding, despite Trump’s opposition, and are even offering to lower a requirement that states put up “matching” funds to qualify for the federal cash.“I’m prepared not only to look at more money for the states to use as they see fit for elections this year, but also to even consider whatever kind of matching requirement we have,” said Roy Blunt, R-Mo., chairman of the Senate panel with responsibility for the issue. “We can continue to work toward an election that produces a result that people have confidence in and done in a way that everybody that wants to vote, gets to vote.”The pandemic erupted this spring in the middle of state primaries, forcing many officials to delay their elections by days, weeks and even months. They had to deal with a wave of poll worker cancellations, polling place changes and an explosion of absentee ballots.Voting rights groups are particularly concerned with the consolidations of polling places that contributed to long lines in Milwaukee, Atlanta and Las Vegas. They fear a repeat in November.As negotiations on the next COVID relief bill begin on Capitol Hill, the final figure for elections is sure to end up much less than the .6 billion envisioned by the House. That figure followed the recommendations of the Brennan Center to prepare for an influx of absentee ballots while providing more early voting options and protecting neighborhood polling places.Even before the pandemic, election offices typically work under tight budgets. Iowa Secretary of State Paul D. Pate, who serves as president of the National Association of Secretaries of State, said the group has been calling on the federal government to provide a steady source of funds, particularly to help address ongoing costs of protecting the nation’s election systems from cyberthreats.For Georgia’s primary last month, election officials spent .1 million of the roughly .9 million the state has received in federal funds. The money was used to send absentee ballot applications to 6.9 million active registered voters and print absentee ballots for county election offices. Some of it also was used to purchase PPE and secure drop-off boxes for counties.Meanwhile, the state elections division has seen a ,000 reduction for the current budget year as Georgia — like the rest of the nation — deals with a decline in revenues due to the pandemic.The state’s remaining federal funds will be used to help cover the costs of developing an online system for voters to request absentee ballots, a less expensive option than sending ballot applications to every voter, and exploring whether installing plexiglass dividers around voting machines could allow more voters in a polling place at one time.In Colorado, which is already a universal vote-by-mail state, the Denver election office has had to reduce its budget by 7.5%, which amounts to nearly 0,000. Jocelyn Bucaro, Denver’s elections director, said the federal funds sent earlier this year helped with purchasing PPE and other pandemic-related supplies.Iowa similarly spent its federal dollars on mail-in ballots and pandemic supplies, Pate said.Vote-by-mail veterans and vendors of the equipment, software, ballots and envelopes that will be needed in November say the window to buy them is quickly closing.“Right now, what I’m seeing in most places is just this kind of indecision. What are we supposed to be planning? Vote by mail or in-person or combination?” said Jeff Ellington, president of Runbeck Election Services, which prints ballots and the special envelopes used to mail them and also supplies high-volume envelope sorters.“Decisions just need to be made so people can start to put a plan into place,” he said.BlueCrest, a Pitney Bowes spinoff, sells high-volume sorting machines that handle up to 50,000 ballot envelopes per hour. That’s the kind of crunch big counties can expect to face on Nov. 3 in states including Wisconsin and Pennsylvania, where Rick Becerra, a vice president at the company, said he’s been talking to officials. The machines average 5,000 each.“I tell them the time is now,” he said.___Cassidy reported from Atlanta. Associated Press writer Frank Bajak in Boston contributed to this report. 6414

The Food and Drug Administration released updated safety standards Tuesday for makers of COVID-19 vaccines despite efforts by the White House to block them, clearing the way for requirements that are widely expected to prevent the introduction of a vaccine before Election Day.In the new guidelines posted on its website, the FDA said vaccine makers should follow trial participants for at least two months to rule out any major side effects before seeking emergency approval. That standard had been a sticking point between the FDA and White House officials, who said it could unreasonably delay the availability of COVID-19 vaccines.President Donald Trump has repeatedly insisted a vaccine could be authorized before Nov. 3, even though top government scientists working on the effort have said that timeline is very unlikely. On Monday Trump said vaccines are coming “momentarily,” in a video recorded after he returned to the White House.Former FDA officials have warned that public perception that a vaccine was being rushed out for political reasons could derail efforts to vaccinate millions of Americans.A senior administration official confirmed Monday that the White House had blocked FDA’s plans to formally publish the safety guidelines based on the two-month data requirement, arguing there was “no clinical or medical reason” for it.But on Tuesday, the FDA posted the guidance on its website, making clear that regulators plan to impose the safety standards for any vaccine seeking an expedited path to market.FDA Commissioner Stephen Hahn said in a statement that he hoped the guidelines would help “the public understand our science-based decision-making process that assures vaccine quality, safety and efficacy.”The requirements are aimed at companies seeking rapid approval through the FDA’s emergency authorization pathway. That accelerated process, reserved for health emergencies, allows medical products onto the market based on a lower bar than traditional FDA approval. But FDA has made clear only vaccines that are shown to be safe and effective will be authorized for coronavirus.Former FDA acting commissioner Dr. Stephen Ostroff said the requirements seem reasonable given the agency is in largely “uncharted territory” in terms of considering emergency use of a vaccine. The agency has only previously cleared one vaccine through the method — a decades-old shot that was authorized to prevent anthrax poisoning in 2005.“There really is no margin for error here,” Ostroff said. “Even when you’re talking about limited use of a vaccine there has to be some level of assurance that there isn’t a risk here that would far outweigh the benefit.”Dr. Peter Marks, the head of FDA’s vaccine division, said Tuesday that the two-month follow-up requirement was chosen to be “something reasonably aggressive, but not too conservative — right in the middle.” He spoke at a symposium organized by Johns Hopkins University.Initial doses of vaccines for emergency use would likely be reserved for medical workers and people with health conditions that make them particularly vulnerable to coronavirus. Full FDA approval for the general population will require significantly more data and is not expected until mid-2021.The White House attempt to block the guidance followed a string of instances in which the Trump administration has undercut its own medical experts working to combat the pandemic. FDA’s Hahn has been attempting to shore up public confidence in the vaccine review process for weeks, vowing that career scientists, not politicians, will decide if the shots are safe and effective.Pfizer CEO Albert Bourla has stoked excitement by saying that he expects data on whether the company’s candidate works to be ready in late October. But a number of variables would still have to align for the company to submit, and the FDA to review and greenlight, a vaccine application before Nov. 3. Pfizer’s competitors Moderna, AstraZeneca and Johnson & Johnson are working on longer research timelines.Vaccine development typically takes years, but the U.S. government has invested billions in efforts to accelerate the process and help multiple drugmakers prepare multiple candidates. All the doses will be purchased by the federal government for use vaccinating the U.S. population.Beyond exposing the rift between the White House and FDA, the delay in releasing the guidelines may have had limited practical effect.FDA scientists have been discussing the guidelines publicly for weeks and have made clear that the recommendations have already been shared with each of the vaccine developers.Former FDA Commissioner Scott Gottlieb said Tuesday that drugmakers depend on the FDA’s science-based endorsement to vouch for the safety and effectiveness of their products.“I can’t imagine a circumstance where a sponsor would challenge or seek to undermine the FDA’s role here,” Gottlieb said at the COVID-19 symposium. “This is precisely the moment when we need an objective, neutral arbiter.”Last week, Gottlieb and six other former FDA commissioners blasted the Trump administration for “undermining the credibility” of the agency in a op-ed calling for the release of the then-stalled vaccine guidelines.“Scientists should make decisions based on data, unfettered by political pressure or the intrusions of ideology or vested interests,” the officials wrote.___AP Medical Writer Lauran Neergaard contributed to this report.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5644

The driver who plowed down pedestrians and cyclists on a New York bike path is a "soldier of the caliphate," the ISIS terror group said on its weekly newspaper, without providing evidence to back up its claim.The attack Tuesday killed eight people and left more than a dozen others injured."One of the Islamic State soldiers in America attacked on Tuesday a number of crusaders on a street in New York City," the al-Naba newspaper reported Thursday.The terror group provided no evidence that ISIS had knowledge of the attack before it happened or it was involved in planning it. The article did not name the attacker.Suspect Sayfullo Habibullaevic Saipov has told authorities that he was inspired to carry out the attack after watching ISIS videos and closely followed the terror group's playbook for an attack.While ISIS did not claim direct responsibility for the attack, it described the attacker as one of its soldiers.Suspect's link to ISISThe 29-year-old Uzbek native was charged with providing material support to ISIS, violence and destruction of motor vehicles, said Joon H. Kim, acting US attorney for the Southern District of New York.Saipov drove a rental truck down a bike path in New York's Lower Manhattan, crashed into a school bus and then jumped out, brandishing imitation firearms, officials said. He was shot by New York police Officer Ryan Nash in the abdomen and taken into custody.He didn't enter a plea Wednesday to the federal terror charges.Saipov was so devoted to ISIS, he wanted to display the terror group's flag in his hospital room, documents show. He had about 90 videos and 3,800 images on a cell phone featuring ISIS propaganda, including video of a beheading, according to the complaint.This is the first time the terror group has put such a claim on its newspaper before releasing it on its media wing, Amaq news agency, which is its first point of publication for claims of responsibility.The wording of the ISIS statement -- not claiming the attack as an outright act of ISIS and saying the person carrying the attack is one of its "soldiers" -- mirrors ISIS' language in statements after an attack in France and the nightclub shooting in Orlando last year.No warning signsThose who crossed Saipov's path are trying to reconcile the man they met and the one they are now hearing about.When approached in the lobby of her Brooklyn apartment building, the suspect's mother-in-law said she was in shock."I don't know what happened," she said.Those who knew him in Tashkent, Uzbekistan, and in at least three states he bounced between since coming to America say they saw no warning signs of Saipov being radicalized."He was happy that he was here, he had a family here, and he was a truck driver and his business was really good," said Makhina Kadirova, a childhood friend.His neighbors described him as a quiet and said his family didn't socialize often.Trump calls for death penaltyOn Twitter, President Donald Trump said Saipov should be executed and added that he "would love" to send him to the Guantanamo Bay detention camp in Cuba."NYC terrorist was happy as he asked to hang ISIS flag in his hospital room. He killed 8 people, badly injured 12. SHOULD GET DEATH PENALTY!' the President tweeted Wednesday night.Presidents typically do not comment on pending criminal cases because their statements could be seen as influencing a potential jury pool.Concrete barriersThe Lower Manhattan bike path where the attack took place has reopened, CNN affiliate WPIX reported, as New York started installing concrete barriers to prevent similar terror incidentsThe work started Thursday as part of a statewide review of shared-use paths, according to the New York State Department of Transportation.A total of 57 barriers are being positioned diagonally along the path, leaving enough space for bicycles but not for larger vehicles, CNN affiliate WABC reported. But some local cyclists think the barriers are problematic."There's no way two bikes can pass each other there and the runners as well," New York City resident James Petty told WABC. "There's going to be accidents."Similar concrete barriers were placed in May after a man drove a car onto a crowded sidewalk in Times Square, killing a teenage woman and injuring at least 22 people.  4290

The Food and Drug Administration (FDA) has cleared the way for a generic version of EpiPen to be created.The FDA’s approval for a generic version, which will be created by Teva Pharmaceuticals, could help alleviate issues like high cost for the life-saving allergy medication.Two year ago, prices for EpiPens skyrocketed, as manufacturer Mylan raised rates from less than 0 for a two-pack to close to 0.But new action by the FDA paves the way for a generic form of the drug, so pharmacies can now offer a generic form to customers, without having to call the doctor to write a new prescription."Oh, it's a huge deal for consumers because the current price is astronomical for a drug that you hope never to use,” says Gerard Anderson, a professor at Johns Hopkins University who has testified about drug prices before Congress.EpiPens have been experiencing shortages, made even worse by the back-to-school orders placed by parents. Anderson says this move to create generic forms should help with the supply and bring prices down.“You’re still gonna get the same drug administered,” says Anderson of the generic forms of the medication. “And so, as a consumer, as a parent, I would choose a less expensive alternative.” 1233

The deaths of 22 more children from flu-related causes were reported Friday by the US Centers for Disease Control and Prevention in its weekly surveillance report.Those deaths bring the total number of children reported to have died to 84 since October, when the current flu season began. Three out of four children who died from the flu had not gotten a flu vaccine, the acting director of the CDC said in a Thursday news conference. "We continue to recommend parents get their children vaccinated even though it's late in the season," Dr. Anne Schuchat said. The season may continue for several more weeks, she added.  633

来源：资阳报